checkAd
    Startseite > Aktien > Acticor Biotech > Nachrichten
    Acticor Biotech
    Aktie
    ISIN: FR0014005OJ5 WKN: A3C6GM SYM: 7V7 Land Frankreich
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    0,6800
     
    EUR
    -12,14 %
    -0,0940 EUR
    Letzter Kurs 14.06.24 Frankfurt
    Geldkurs
    14.06.24
    0,6320
     
    EUR
    3.165 STK
    Briefkurs
    14.06.24
    0,7340
     
    EUR
    2.725 STK

    Acticor Biotech Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Acticor Biotech Updates Its Glenzocimab Clinical Development Plan for the Treatment of Cardiovascular Emergencies
    03.06.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024
    27.05.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
    15.05.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023
    30.04.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment
    25.04.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
    15.04.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024
    05.04.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of February 29, 2024
    18.03.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros
    15.03.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech Launches a Capital Increase of a Minimum of 7 Million Euros
    14.03.24 · Business Wire (engl.) · Acticor Biotech
    The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks
    07.02.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2024
    06.02.24 · Business Wire (engl.) · Acticor Biotech